drugset / Trial / NCT04761731
To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients
Phase 4
Completed
31 enrolled
Linical Korea
Astellas Pharma Korea, Inc. · collabNational Cancer Center, Korea · collab
NaSingle-groupOpen-labelScreening
Summary
This study's objective is to evaluate the incidence rate of acute rejection reactions after 24 weeks treatment with ADVAGRAF® following 3 months treatment with tacrolimus in new liver transplant recipients. Treatment conversion will take place from twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
Timeline
- Start
- 2015-07
- Primary completion
- 2017-12-14
- Completion
- 2017-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tacrolimus | Small molecule | — | — |
Indications
No indication recorded.